Outcomes after transplantation for “failed” Fontan: A single-institution experience

Ryan R. Davies, MD,^a Robert A. Sorabella, MD,^b Jonathan Yang, MD,^b Ralph S. Mosca, MD,^c
Jonathan M. Chen, MD,^d and Jan M. Quaegebeur, MD, PhD^b

Objective: Despite the excellent outcomes in the current era after the Fontan procedure, it continues to have an inherent risk of failure. Cardiac transplantation provides 1 option for treating these patients; however, the indications for, timing of, and outcomes after, transplantation remain undefined. We examined our own institutional experience with transplantation for failed Fontan.

Methods: The records of 155 patients transplanted for congenital heart disease at a single institution from June 1984 to September 2007 were reviewed. Of these patients, 43 had undergone a previous Fontan procedure (25 male, 15 female; median age, 14.5 years; range, 1–47; 23 classic Fontan, 13 lateral tunnel, 4 extracardiac conduit, and 3 revised to shunt). The predictors of short- and long-term survival were evaluated, and the Fontan patients were compared with all other patients with congenital heart disease ($n = 129$, 78 male, 51 female).

Results: The most common indications for transplantation included protein-losing enteropathy (PLE) (39.5%), chronic heart failure (41.8%), and acute post-Fontan failure (9.3%). The transplants performed in Fontan patients were more likely to require pulmonary artery reconstruction (85.4% vs 42.9%; $P < .0001$) and had longer cardiopulmonary bypass times (278 vs 179 minutes; $P < .0001$). The 90-day mortality rate was greater in the Fontan group (35.0% vs 20.0%; $P = .055$). No correlation was observed between the interval from Fontan to transplantation and mortality; however, renal failure was a strong predictor of early mortality (odds ratio, 10.8; 95% confidence interval, 1.5–75.7).

Conclusions: Transplantation is an acceptable treatment for patients with a failed Fontan. Clinical factors (instead of the indication for transplantation) appear to have the greatest correlation with early mortality. (*J Thorac Cardiovasc Surg* 2012;143:1183-92)

Supplemental material is available online.

In 1971, Fontan first described placing the systemic and pulmonary circulations in series as a treatment for tricuspid atresia.¹ Since then, the use of the Fontan procedure has been expanded to include a variety of congenital heart defects in which 2 functional ventricles cannot be constructed. Despite the extraordinary advances that the Fontan procedure and its modifications represent in the care of children with single ventricle lesions, there has always been an

ongoing concern about the long-term future of the circulation driven by a single ventricle.^{2,3} More recent examinations of post-Fontan outcomes have confirmed the long-term challenges facing these patients in the early and late postoperative period.⁴

A range of other pathologic processes (often incompletely understood) can result in progressive morbidity and mortality after the Fontan procedure, including Fontan circuit failure with normal ventricular function, severe growth retardation, intractable arrhythmias, PLE, thrombotic circuit occlusion, pulmonary arteriovenous malformations, and, rarely, acute post-Fontan failure. Although some of these pathologic features might be amenable to Fontan revision, especially where correctable anatomic problems or focal atrial arrhythmias predominate, cardiac transplantation often provides the only real alternative for these patients. Accordingly, we chose to examine our own experience with cardiac transplantation after failed Fontan to examine the outcomes and identify the predictors of early and late post-transplant mortality.

METHODS

Patient Population

A retrospective review was performed to identify all patients (both adult and pediatric) undergoing primary cardiac transplantation at the Columbia

From the Nemours Cardiac Center,^a A.I. duPont Hospital for Children, Wilmington, Del; Children's Hospital of New York-Presbyterian,^b Columbia University College of Physicians and Surgeons, New York, NY; New York University Langone Medical Center,^c New York, NY; and Joan and Sanford Weill Medical College of Cornell University,^d New York, NY.

Disclosures: Authors have nothing to disclose with regard to commercial support. Received for publication April 19, 2011; revisions received Sept 23, 2011; accepted for publication Dec 14, 2011.

Address for reprints: Ryan R. Davies, MD, Nemours Cardiac Center, A.I. duPont Hospital for Children, 1600 Rockland Rd, Wilmington, DE 19803 (E-mail: rdavies@nemours.org).

0022-5223/\$36.00

Copyright © 2012 Published by Elsevier Inc. on behalf of The American Association for Thoracic Surgery

doi:10.1016/j.jtcvs.2011.12.039

Abbreviations and Acronyms

CHD = congenital heart disease
CI = confidence interval

University Medical Center from January 1, 1984, to January 1, 2007. The institutional review board for Columbia University Medical Center approved the study, and the requirement for informed consent was waived. A total of 172 patients with congenital heart disease (CHD) underwent transplantation within the study period. Among the patients with CHD, 43 (25.0%) had undergone a previous Fontan operation; these patients formed the basis for the present analysis.

Surgical Technique

Because of the potential need for extensive recipient reconstruction, the margins of donor tissue excised were extended, usually to include the aortic arch and proximal head vessels, branch pulmonary arteries to the hilum, and superior vena cava and innominate vein. The preferred method of graft preservation was a single dose of cold Celsior solution (Genzyme Corporation, Cambridge, Mass) given by pressurized infusion into the aortic root. Heart transplantation was performed under hypothermic cardiopulmonary bypass, with deep hypothermic circulatory arrest as needed. Arterial cannulation was preferentially performed in the aorta, with bicaval venous cannulation; groin cannulation was used as necessary. In the early part of the series, the biatrial anastomosis (as described by Lower and Shumway⁵) was used in most patients, but in more recent patients, with the demonstration of its several advantages,⁶ the bicaval technique has been preferred, except in cases in which anatomic considerations preclude its use.⁷

Data Collection

A hospital chart review was conducted for each identified patient and their donor, and the data were entered into a computerized database. The donor and recipient demographic and intraoperative and postoperative variables were acquired. The follow-up period for the patients with failed Fontan circulation ranged from 0.4 to 19.5 years (median, 30.7 months; mean, 52.5). The survival data were cross-referenced with the Social Security Master Death Index (available at: <http://www.ssdi.rootsweb.ancestry.com>).

Statistical Analysis

Univariate and multivariate statistical methods were used to identify and estimate the risk factors for all-cause mortality and 30-, 60-, and 90-day mortality. In addition, the study population was compared (using similar techniques) with all other patients with CHD and with all non-CHD patients who underwent transplantation during the same period.

The methods of statistical analysis included the chi-square test for comparisons of dichotomous risk factors with negative outcomes, the Mantel-Haenszel chi-square test for comparisons taking into consideration disease severity, and the Wilcoxon test for comparisons of continuous variables with negative outcomes ($P < .05$). Life-table estimates (Kaplan-Meier) were calculated using the LIFETEST procedure of SAS, version 9.13, for Windows (SAS Institute, Cary, NC) with the log-rank test for differences between strata.

RESULTS**Baseline Demographics and Clinical Condition at Transplantation**

Fewer patients were younger than 5 years (9.3% vs 36.4%, $P = .0007$) in the Fontan group than in the group of other patients with CHD, although the mean age was

similar between the 2 groups (15.8 vs 13.7 years, $P = .3$). Patient gender and the indicators of clinical condition at transplantation did not differ significantly between the 2 groups (Table 1). Both groups had a high incidence of previous sternotomy, and single ventricle diagnoses were more common among the Fontan patients (Table 1). The Fontan patients had lower albumin levels in the week before transplantation (3.7 vs 4.0, $P = .02$). Among the patients with a previous Fontan operation, the Fontan circuit was a classic (atriopulmonary connection) Fontan in 23 patients (53.5%), a lateral tunnel in 13 (30.2%), an extracardiac connection in 4 (9.3%), and had been taken down in 3 (7.0%; Table 2).

Previous Surgical Interventions

Of all 172 patients undergoing transplantation for CHD, 72 (41.8%) had a single ventricle. Of these 72 patients, 5 (6.9%) had undergone no previous palliation, 10 (13.9%) had had only a shunt placed, 14 (19.4%) had undergone a classic or bidirectional Glenn procedure but no Fontan procedure, and 43 (59.7%) had undergone the Fontan procedure.

The median age at Fontan completion was 5.4 years (mean, 7.4; range, 1–25). Nine patients (20.9%) underwent the Fontan procedure at our institution (Table 3); the remainder were referred for transplant evaluation after a Fontan procedure at other institutions. The mean interval from the initial Fontan operation to transplantation was 8.6 years (range, 6 days to 24.5 years).

Hemodynamics

The mean pretransplant transpulmonary gradient was 7.0 mm Hg, with a mean Fontan conduit pressure of 18.4 mm Hg (range, 13–25 mm Hg). In the setting of extensive aortopulmonary collateral flow, the pulmonary vascular resistance could not be calculated reliably.

Transplant Procedure and Operative Technique

The number of days on the waiting list was similar for both groups (Fontan, 56.9 vs non-Fontan, 63.5 days; $P = .8$). Femoral arterial and venous cannulation was required in 16 Fontan patients (37.2%). Most other patients had bicaval venous and aortic arterial cannulations. Rarely used cannulation sites included the subclavian artery or carotid artery and the axillary vein or an extracardiac conduit. Fontan patients were more likely to require pulmonary artery reconstruction (85.4% vs 42.9%, $P < .0001$), although the need for reconstruction of the venous return (19.5% vs 17.7%, $P = .8$) or transplantation to a single lung (4.9% vs 8.0%, $P = .5$) was similar (Table E1). Most commonly, the recipient pulmonary artery bifurcation or right pulmonary artery required reconstruction. Repair of venous return was most commonly required because of the presence of a left superior vena cava. Donor tissue (either pulmonary

TABLE 1. Baseline demographics among 43 patients with “failed Fontan” compared with all other transplants for congenital heart disease (n = 129)*

Demographic	Fontan (n = 43)	Other CHD (n = 129)	P value
Gender (male)	28 (65.1%)	78 (65.1%)	.59
Blood type			
A	19 (46.3%)	49 (41.5%)	.4
AB	4 (9.6%)	6 (5.1%)	
B	2 (4.9%)	12 (10.2%)	
O	16 (39.1%)	51 (42.2%)	
Diagnosis			
Single ventricle	43 (100.0%)	29 (22.6%)	<.0001†
Transposition of the great arteries	8 (18.6%)	28 (22.1%)	.6
Tetralogy of Fallot	1 (3.3%)	15 (15.2%)	.09
Pulmonary atresia	4 (13.3%)	22 (22.0%)	.3
Pulmonary stenosis	12 (38.7%)	19 (19.6%)	.03†
Hypoplastic left heart syndrome	6 (14.6%)	18 (15.4%)	.9
Tricuspid atresia	11 (26.8%)	2 (1.6%)	<.0001†
Surgical history			
Previous sternotomy	43 (100.0%)	96 (74.4%)	.0002†
Aortopulmonary shunt‡	31 (72.3%)	80 (62.0%)	.2
Classic or bidirectional Glenn	19 (44.2%)	22 (17.1%)	.0003†
Both Glenn and shunt	16 (37.2%)	18 (14.0%)	.0009†
Hemi-Fontan	2 (4.9%)	0 (0.0%)	.02†
Clinical condition			
Hospitalized	21 (60.0%)	53 (64.6%)	.6
Intensive care unit	14 (40.0%)	29 (35.4%)	.6
Mechanical ventilation	7 (20.0%)	19 (21.4%)	.9
Creatinine >1.5	6 (15.8%)	6 (14.6%)	.9
Ventricular assist device	0 (0.0%)	1 (0.9%)	.5
Extracorporeal membrane oxygenation	5 (12.8%)	5 (4.7%)	.08

*Percentages indicate percentage of patients with a risk factor among those for whom data were available for that risk factor. †Statistically significant. ‡Including Blalock-Taussig shunts and other surgical systemic-to-pulmonary shunts.

arterial or innominate venous tissue) was the most common material used for reconstruction, although bovine or pericardial patches were also used, as was atrial tissue (Table E1). One patient with situs inversus required interatrial baffles to direct left-sided venous return to the donor right atrium. Baffles were also used to redirect totally anomalous pulmonary venous return into the donor left atrium in another case.

The cardiopulmonary bypass times (mean, 278 vs 179 minutes; $P < .0001$) and aortic cross-clamp times (mean, 104 vs 81 minutes; $P = .09$) were longer in the Fontan group. The total donor organ ischemic times were slightly longer in the Fontan group (258 vs 226 minutes, $P = .04$). Twelve patients (27.9%) in the Fontan group required a period of circulatory arrest (Table E1), and a trend was seen toward longer circulatory arrest times compared with the circulatory arrest required in

the other patients with CHD (mean, 50.3 vs 26.1 minutes; $P = .09$).

Early Post-Transplant Outcomes

Morbidity. Neurologic events occurred in 8 patients in the Fontan group, including seizures in 1, strokes in 6, and a subdural hemotoma in 1 patient (Table E2). Two of the patients with stroke (33.3%) died before hospital discharge. In both cases, the stroke was likely related to cardiac arrest, hypotension, and cerebral hypoxia. Of the other 4 patients, 1 had severe congenital cerebrovascular anomalies identified in the postoperative period. The other 3 appeared to have hypoxic/ischemic strokes related to postoperative hypotension or cardiac arrest.

Five patients (11.6%) in the Fontan group required dialysis in the postoperative period (Table E3). Only 1 of these patients had preoperative renal dysfunction, most had complicated postoperative courses, including sepsis and multiorgan system failure. All 5 patients died before discharge. Six patients (14.0%) required reoperations for bleeding; the in-hospital mortality within this group was 50%. Drug-treated infections (including pneumonia, septicemia, and urinary tract infections) occurred in 21 patients (48.8%). Of these patients, 7 (33.3%) died within 90 days of transplantation. Neither postoperative (32.9 vs 28.1 days, $P = .52$) nor total (46.4 vs 58.4 days, $P = .25$) length of stay differed between the Fontan and non-Fontan CHD groups.

Mortality. Trends were seen toward increased mortality in the Fontan group at 30 days (25.0% vs 15.6%, $P = .16$) and 60 days (27.5% vs 18.3%, $P = .21$) but these did not reach statistical significance. The 90-day mortality rate was greater among patients in the Fontan group than among the other patients with CHD (35.0% vs 20.0%, $P = .055$; odds ratio [OR], 2.15; 95% confidence interval [CI], 0.97–4.76), although this was primarily the result of the high mortality early in our experience (before 2000; 40.9% vs 18.9%, $P = .046$). Patients with “failed Fontan” who had undergone transplanted after 1999 had similar mortality to those with other forms of CHD (27.8% vs 22.2%, $P = .64$). In this later group, early mortality occurred entirely among the adult patients (Table 4).

Among the non-Fontan patients, the univariate predictors of 30-day mortality included female gender (OR, 3.3; 95% CI, 1.2–9.5), age younger than 1 year (OR, 4.1; 95% CI, 1.4–12.5), hospitalization at transplantation (OR, 4.5; 95% CI, 0.5–38.9), the need for extracorporeal membrane oxygenation (OR, 15.4; 95% CI, 1.5–158.2), pretransplant need for mechanical ventilation (OR, 6.8; 95% CI, 1.9–24.4), history of aortopulmonary shunt without a subsequent Glenn procedure (OR, 2.7; 95% CI, 0.9–8.4), and a diagnosis of tetralogy of Fallot (OR, 3.6; 95% CI, 1.0–12.8).

Similar factors were important among the patients in the Fontan group (although the sample size limited the power of the analyses): hospitalization (0.0% vs 28.6%, $P = .0492$),

TABLE 2. Patients undergoing transplantation after a “failed Fontan” procedure

Pt. no.	Fontan type	Gender	Age at Fontan	Age at transplantation (yr)	Transplantation year	Indication	Outcome	Cause of death
39	Classic	M	??	16	1989	Chronic failure	Died, 16 yr	Chronic rejection
49	Classic	M	3 y	21	1990	PLE	Alive	
53	Classic	M	4 y	15	1990	PLE	Died, POD 30	Sepsis and ARDS
69	Classic (fenestrated)	M	10 y	15	1992	PLE	Alive	
73	Take-down	F	5 y	15	1992	Chronic failure	Died, POD 0	Primary failure
81	Classic	M	2 y	10	1992	Chronic failure	Alive	
82	Lateral tunnel	M	3 y	3	1992	Acute failure	Died, POD 1	Bleeding
83	Classic	M	16 y	16	1992	Chronic failure	Died, 5 yr	Chronic rejection
787	Classic	M	10 y	26	1992	Chronic failure	Alive	
790	Classic	M	13 y	23	1992	Chronic failure	Died, POD 1	Bleeding
87	Classic	F	5 y	18	1993	Pulmonary AVM	Alive	
791	Classic	M	14 y	20	1993	PLE	Died, 14 yr	Chronic rejection
91	Lateral tunnel (fenestrated)	M	1 y, 1 mo	1	1994	Acute failure	Alive	
98	Classic	M	1 y, 11 mo	11	1994	PLE	Died, POD 2	Bleeding
99	Classic	M	7	12	1994	Chronic failure	Died, 6 wk	Stroke
379	Lateral tunnel	F	5	20	1994	Chronic failure	Died, POD 0	Bleeding
794	Classic	M	10	26	1994	Chronic failure	Died, 7 yr	Chronic rejection
105	Classic	F	3	8	1995	PLE	Alive	
113	Classic (fenestrated)	F	1 y, 8 mo	8	1995	PLE	Died, 6 yr	Chronic rejection
115	Lateral tunnel	M	15 y	16	1995	Chronic failure	Alive	
145	Classic (fenestrated)	F	6 y	7	1998	Chronic failure	Died, POD 0	Bleeding
155	Classic	M	2 y	12	1998	Chronic failure	Alive	
801	Lateral tunnel	F	18 y	31	1998	PLE	Died, POD 8	Sepsis
171	Classic	F	12 y	23	2000	PLE	Alive	
198	Lateral tunnel	M	2 y	7	2002	Chronic failure	Alive	
203	Taken-down	F	2 y	2	2003	Acute failure	Alive	
204	Classic	M	2 y	13	2003	Chronic failure	Alive	
205	Take-down	F	2 y	7	2003	Pulmonary AVM	Alive	
207	Lateral tunnel	M	3 y	9	2003	Plastic bronchitis	Alive	
234	Lateral tunnel (fenestrated)	F	9 y	9	2004	Chronic failure	Alive	
768	Classic	M	10 y	31	2004	PLE	Alive	
248	Lateral tunnel (fenestrated)	M	15 y	16	2005	PLE	Died, 10 wk	Sepsis
249	Extracardiac	F	9 y	13	2005	PLE	Died, 8 wk	Sepsis
251	Extracardiac	M	5 y	19	2005	Acute failure	Died, POD 0	Hyperkalemic arrest
258	Lateral tunnel (fenestrated)	M	3 y	3	2005	Chronic failure	Alive	
261	Classic	F	4 y	22	2005	PLE	Died, 8 wk	Sepsis
510	Extracardiac (fenestrated)	F	2 y	8	2006	PLE	Alive	
726	Lateral tunnel	F	2 y	10	2006	Pulmonary AVM	Died, 4 mo	Acute rejection
740	Extracardiac (fenestrated)	M	1 y, 6 mo	15	2006	PLE	Alive	
772	Classic	M	25 y	47	2006	Chronic failure	Alive	
757	Classic	M	14 y	38	2007	PLE	Died, POD 1	Bleeding
844	Lateral tunnel	M	2 y	13	2008	PLE	Alive	
866	Lateral tunnel	M	2 y	13	2009	Chronic failure	Alive	

Pt. no., Patient number; M, male; PLE, protein-losing enteropathy; POD, postoperative day; ARDS, acute respiratory distress syndrome; F, female; AVM, arteriovenous malformation.

TABLE 3. Details of Fontan procedure among patients who underwent Fontan procedure

Pt. no.	Year	Diagnosis	Previous procedures	Clinical course
82	1992	DILV with L AV valve atresia, L TGA	Pulmonary banding	Postoperative ventricular failure requiring ECMO implantation, transplant 9 d later
91	1994	DORV with interrupted aortic arch	Pulmonary banding	Postoperative ventricular failure requiring ECMO implantation, transplant 6 d later
115	1995	Single ventricle with single AV canal, PS	None	Developed AV valve incompetence requiring mechanical valve replacement within 2 mo, progressively worsening cardiac function, transplant within 6 mo
198	1997	Tricuspid atresia, VSD	Pulmonary banding	Long-term development of dilated cardiomyopathy, transplanted 5 y later
234	2004	Unbalanced AV canal with aortic atresia, hypoplastic left heart	Norwood with central shunt, BDG w/pulmonary arterioplasty	Fontan procedure included AV valve annuloplasty and patch enlargement of the L PA, developed worsening AV valve regurgitation, high PA pressures, thrombus in conduit, transplanted approximately 6 wk later
248	1992	Dextrocardia, DORV, common atrium, PS, TGA, TAPVR	Central shunt, repair of TAPVR	Uncomplicated, developed PLE, transplanted 13 yr later
768	1983	DILV	Pulmonary banding	Uncomplicated, developed PLE, transplanted 19 yr later
844	1997	HLHS	Norwood stage 1, BDG	Uncomplicated, developed PLE, systemic-pulmonary collaterals causing hemoptysis, transplanted 11 years later
866	1997	HLHS	Norwood stage 1, BDG	Fontan procedure complicated by coagulopathy, massive epistaxis, and eventual hypotensive cardiac arrest approximately 1 wk postoperatively, then a prolonged chylothorax; subsequent course was uncomplicated until development of chronic heart failure, transplanted 12 yr later

Pt. No., Patient number; DILV, double inlet left ventricle; L, left; AV, atrioventricular; TGA, transposition of the great arteries; ECMO, extracorporeal membrane oxygenation; DORV, double outlet right ventricle; PS, pulmonary stenosis; VSD, ventricular septal defect; BDG, bidirectional Glenn; PA, pulmonary atresia; TAPVR, totally anomalous pulmonary venous return; HLHS, hypoplastic heart syndrome.

extracorporeal membrane oxygenation (OR, 5.6; 95% CI, 0.8–40.1), and previous shunt without a Glenn procedure (OR, 4.3; 95% CI, 0.8–22.5). However, gender was not a significant predictor of poor outcomes (OR, 1.14; 95% CI, 0.3–5.0). In addition, a creatinine level greater than 1.5 was also associated with greater early mortality (OR,

10.8; 95% CI, 1.5–75.7). Early mortality was lower among patients transplanted after 1999 (Table 4). A trend was seen toward a reduction in 30-day mortality among patients palliated with a Glenn procedure (17.6%) compared with

TABLE 4. Mortality by era of transplantation (among Fontan patients, n = 43)

Mortality	Before 1999	After 1999	P value
30-d	8/23 (34.8%)	2/20 (10.0%)	.0550
Age<18 y	5/16 (31.3%)	0/14 (0.0%)*	
Age≥18 y	3/7 (42.9%)	2/6 (33.3%)*	
60-d	9/23 (39.1%)	2/20 (10.0%)	.0290
Age<18 y	6/16 (37.5%)	0/14 (0.0%)*	
Age≥18 y	3/7 (42.9%)	2/6 (33.3%)*	
90-d	9/23 (39.1%)	5/20 (25.0%)	.3240
Age<18 y	6/16 (37.5%)	2/14 (14.3%)†	
Age≥18 y	3/7 (42.9%)	3/6 (50.0%)†	

*Age < 18 years vs age ≥ 18 years; P = .02. †Age < 18 years vs age ≥ 18 years; P = .09.

TABLE 5. Mortality at 30, 60, and 90 days among patients with “failed Fontan” (n = 43)

Variable	Patients (n)	Mortality (%)		
		30 d	60 d	90 d
PLE	15	14.3	14.3	35.7
Acute failure/postcardiotomy shock	4	50.0	50.0	50.0
Chronic failure	17	29.4	35.3	35.3
Plastic bronchitis	1	0.0	0.0	0.0
Pulmonary AVMs	3	0.0	0.0	0.0
Classic	22	22.7	27.3	31.8
Extracardiac	4	25.0	25.0	50.0
Lateral tunnel	11	27.27	27.3	36.4
Take-down	3	33.3	33.3	33.3

PLE, Protein-losing enteropathy; AVMs, arteriovenous malformations.

FIGURE 1. Fifteen-year Kaplan-Meier post-transplant survival estimates illustrated as a function of previous Fontan procedure among patients with a history of congenital heart disease (CHD) ($P = .12$).

the single ventricle patients at all other stages (unpalliated, shunted, or Fontan; 28.6%; OR, 0.54; 95% CI, 0.17–1.68).

The elapsed time between the Fontan procedure and transplantation did not affect 30-day survival. Neither did the indication for transplantation, although the sample size limited the statistical analysis, but the patients transplanted for acute cardiac failure had poor outcomes (Table 5). Among the patients with PLE, a creatinine level greater than 1.5 was a predictor of 30-day mortality (100% vs 13.4%, $P = .047$); however, the presence of ascites (OR, 0.75; 95% CI, 0.05–11.6) or albumin less than 3.0 within 1 month of transplantation (OR, 0.24; 95% CI, 0.02–3.01) were not.

Late Post-Transplant Outcomes

The long-term survival rate among the 43 patients with failed Fontan circulation was 62.4% at 1 year, 58.7% at 5 years, and 47.5% at 10 years. Although a trend was seen toward worse long-term survival among the Fontan patients, this mostly resulted from increased mortality within the first few months after transplantation. After the early postoperative period, the long-term risk of mortality was similar (Figure 1).

Among all patients with single-ventricle CHD, a trend was seen toward improved survival among patients transplanted after palliation with either a bidirectional or classic

FIGURE 2. Fifteen-year Kaplan-Meier estimates of post-transplant survival stratified by the indication for transplantation among the 40 patients with “failed Fontan” circulation. AVM, Arteriovenous malformation.

FIGURE 3. Fifteen-year Kaplan-Meier estimates of post-transplant survival among all patients transplanted with a single ventricle stratified by the type of previous surgical palliation performed ($P = NS$).

Glenn procedure compared with those who did not make it to a Glenn procedure and those who underwent a Fontan procedure (Figure 3). Overall, the survival of patients with a single ventricle was lower than that for patients with 2 functional ventricles before transplantation ($P = .0321$; Figure 4). The indication for transplantation did not predict long-term survival (Figure 2). Survival was also similar regardless of whether the patients had ascites at of transplantation.

Transplantation resulted in resolution of PLE in most long-term survivors. Data were not available for 2 patients, and 5 patients died before discharge. Of the remaining 9 patients, 1 did not have resolution of PLE, most likely

secondary to complete occlusion of the central veins above the superior vena cava; 1 required 646 days to normalize his albumin level, but he also had a diagnosis of cirrhosis and hepatitis C. The other 7 patients had normal albumin levels at a median of 44 days (range, 7–114) after transplantation. Plastic bronchitis resolved, with normal bronchoscopy findings after transplantation; the pulmonary arteriovenous malformations also resolved, but took longer.

Causes of Death Within Failed Fontan Group

Three phases of mortality were observed. Within the first week, most patients who died did so of bleeding causes. Of the 8 deaths within 1 week of transplantation, 6 were

FIGURE 4. Fifteen-year Kaplan-Meier estimates of post-transplant survival among all patients undergoing transplantation from 1987 to 2004. Stratified by presence or absence of congenital heart disease (CHD), and number of functional ventricles before transplantation.

secondary to bleeding, 1 was due to cardiovascular collapse after a prolonged period of cardiopulmonary bypass, and 1 was due to acute postoperative right ventricular failure. Since 1995, only 1 patient has died of intractable postoperative bleeding (Table 2). From 1 week to 3 months, most of the 5 deaths resulted from infectious complications ($n = 4$, 80%); rejection was the primary cause of death for the remaining 5 patients.

The predictors of mortality within 7 days of transplantation included creatinine greater than 1.5 (OR, 14.0; 95% CI, 1.9–102.9) and the need for mechanical ventilation (OR, 5.5; 95% CI, 0.8–37.6).

DISCUSSION

Placement of the pulmonary circulation in series with the systemic circulation remains an elegant solution to the patient with CHD without a functional second ventricle. Recent series have demonstrated excellent early and late results after the Fontan procedure; however, even contemporary series have a persistent percentage of patients with Fontan failure. Technical issues and the timing of the Fontan procedure may play a role in some cases of failure; however, even the “perfect” Fontan procedure cannot provide a permanent solution for every patient.^{1,2}

Although not addressed in the present study, many causes of Fontan failure are amenable to surgical or interventional correction, including atrial arrhythmia ablation, atrioventricular valve repair or replacement, and conduit revision.^{3,4} However, the results of surgical or catheter-based treatments of Fontan failure have often been poor—whether performed for PLE, arrhythmias, or progressive heart failure.^{3,8–10} This has led many centers to undertake cardiac transplantation as a more definitive treatment of the failed Fontan procedure.^{11–14} At Columbia, we have used cardiac transplantation as the preferred treatment for Fontan failure in the absence of specific correctable anatomic issues. With the increasing prevalence of adults with CHD, the number of patients listed for cardiac transplantation with Fontan failure can also be expected to increase.¹⁵

Unfortunately, few studies have systematically evaluated patients who have undergone transplantation after a failed Fontan procedure to assess their outcome compared with other patients with CHD, leaving clinicians largely in the dark about the expected outcomes after transplantation. In the present study, we report our single-institution experience with transplantation as treatment of the failing Fontan circulation.

The early mortality after transplantation was high but, consistent with our experience among all patients with CHD, recent survival has improved compared with earlier experience.¹⁶ Most notably, since 2000, only a single patient has died of postoperative bleeding. The early experience included a significant learning curve with the

methods of pulmonary artery reconstruction and reconstruction of the venous return, including the use of baffles to correct pulmonary venous return, as appropriate. The reduction in postoperative hemorrhagic deaths suggests that many of these technical hurdles have been overcome.

Despite these improvements, transplantation for the failing Fontan circulation remains a technically demanding surgery, frequently needing complex pulmonary artery reconstruction, long bypass times, and periods of deep hypothermic circulatory arrest. Increased experience with these technical aspects and the resultant decreases in operative times and technical complications likely played a role in the decreased incidence of bleeding and early postoperative death. Other possible contributors to the improvement in early outcomes include the increased use of antifibrinolytic agents, more careful patient selection (both transplantation of patients before the onset of end-organ—especially liver—failure and the refusal to transplant patients already in liver failure), and more meticulous attention to hemostasis with the recognition of the significant contribution of hemorrhage to early postoperative death.

Recent data from Kanter et al¹⁷ reports mortality among the Fontan patients that is equivalent to that among non-Fontan transplantations (including, presumably, patients with cardiomyopathy). Although superficially at odds with our results, close inspection shows that the differences are mostly related to the patients included in the study; in our most recent era, we had no mortality within 30 days among the pediatric Fontan patients. Adult patients provide additional challenges, especially with regard to bleeding in patients with hepatic congestion and relative hepatic dysfunction. Evaluations of hepatic function are performed in all patients, although biopsy usually shows findings consistent with congestive heart failure. Most patients with a failing Fontan will have some degree of liver dysfunction and coagulopathy, but quantifying this dysfunction is helpful in planning the implantation procedure.

While mundane, it bears repeating that planning for sternal re-entry is a critical part of the procedure; cross-sectional imaging should be used as necessary to determine a safe reentry strategy in these patients where injury to the right atrium may quickly result in massive systemic air embolus.

The other critical technical aspect of the operation is reconstruction of the pulmonary arterial pathway. Although most reconstructions in our series were performed using donor tissue, other materials have also been used successfully. Therefore, waiting for the “perfect” donor from whom extensive donor tissue can be included as a part of the cardiectomy could needlessly prolong the waiting list time.

Close coordination between the donor and recipient surgeons during these procedures is essential, given the combination of multiple reoperative surgery, long travel times for retrieval of pediatric organs, and complex anatomic

reconstruction during allograft implantation. Failure to allow for the recipient dissection time can result in the donor organ spending additional time on ice, compromising post-transplant cardiac function. We have demonstrated mean organ ischemic times of less than 5 hours, only 30 minutes longer than the patients in the congenital group.

Other investigators have suggested that, among single ventricle patients, transplantation might be best considered as an alternative to the Fontan procedure in high-risk patients, because patients transplanted after the Glenn procedure (before Fontan completion)—even in an earlier and smaller series from our own institution—had significantly better outcomes than those who first underwent a Fontan procedure.^{12,13} However, in the present larger series, we did not find a dramatic improvement in outcomes when transplantation occurred before Fontan completion, although a trend was seen toward improved results among patients with only a Glenn procedure. This might have been a result of random variation between the outcomes in groups with small sample sizes or of differences in patient selection across series. Alternatively, it might indicate the high morbidity level among patients with a Glenn procedure referred for transplantation in an era with excellent Fontan outcomes.^{18,19}

The mean age at Fontan in these patients was older than 7 years, substantially older than in the typical Fontan series. This likely reflects the poorer results obtained with late Fontan palliation.¹⁹ Although most patients underwent transplant evaluation for single ventricle failure, other indications included PLE and acute failure after Fontan conversion. We did not identify any group of patients unlikely to benefit from transplantation (whether by diagnosis or by interval between the Fontan procedure and transplantation), although, clearly, patients with acute post-Fontan failure have high mortality rates even with transplantation.

Unlike other transplant candidates, elevated pulmonary vascular resistance is rarely a problem in the patients with failed Fontan circulation. Despite the often elevated pressures within the Fontan circuit, the transpulmonary gradients remained low in these patients. Accurate measurement of pulmonary vascular resistance in patients with Fontan circulation is largely precluded by the presence of significant aortopulmonary collaterals. We have traditionally thought that any increase in pulmonary vascular resistance tolerated by Fontan patients—living without a pulmonary ventricle—would be too small to pose a risk to a healthy donor right ventricle. However, we speculate that accurate measurements of pulmonary vascular resistance might demonstrate some patients in whom transplantation would be less likely to be successful, given that at least 1 patient died after right ventricular failure during allograft implantation.

Management of the aortopulmonary collaterals in the pre- and post-transplant period remains challenging. Although coiling might enable more accurate determination

of pulmonary vascular resistance, most of these patients are cyanotic and loss of this pulmonary blood flow would likely result in worsening hypoxia. In patients with significant collaterals, this may necessitate alterations in the cardiopulmonary bypass strategy with periods of low flow or circulatory arrest to minimize pulmonary venous return. However, in the post-transplant period we have a low threshold for returning to the catheterization laboratory for percutaneous closure of remaining collaterals, especially in patients showing evidence of high cardiac output.

Consistent with other reports, patients with PLE did not have greater mortality (even in the presence of ascites), and resolution of PLE in the post-transplant period was common.¹⁴ Other treatments for PLE have yielded inconsistent results, and the mortality rate at 5 years can exceed 50%.^{8,20} In the absence of clear and well-defined hemodynamic problems amenable to correction, transplantation offers the best opportunity for treatment of PLE in patients with Fontan circulation. Patients with pulmonary arteriovenous malformations and plastic bronchitis also had similar post-transplant outcomes, suggesting that these patients might benefit significantly from early transplantation, although resolution of arteriovenous malformations may take several months.

The optimal timing of transplantation in patients with a failing Fontan circulation remains problematic. Overall, the tendency has been to list patients for transplantation earlier in more recent eras (this may be a significant contributor to improved outcomes). In that way, we are able to transplant patients with only a failing Fontan, not a failing Fontan with bad ventricular function, poor nutrition, and marginal renal function.

Although the onset of PLE or ascites did not increase post-transplant mortality, other clinical parameters did. Despite the small sample size, it was clear that once patients had developed renal dysfunction, survival after transplantation was markedly decreased. Although preoperative renal failure is a predictor of poor outcomes in all patients undergoing heart transplantation, patients with 2 ventricles might be easier to bridge to transplantation while optimizing end-organ perfusion.²¹ Single ventricle physiology makes the use of ventricular assist devices (for both ventricular unloading and optimization of perfusion) difficult, and the poor results suggest that extracorporeal membrane oxygenation is not a preferred alternative as a bridge to transplantation.²¹ Worsening renal function, where it is thought to be due to low-cardiac output and possibly reversible, might be considered an indication for acceleration of listing and earlier transplantation before the development of complete renal failure.

This suggests that patients with failing Fontan circulation should be evaluated early for transplantation, and transplantation should be performed before Fontan failure, resulting in significant systemic hypoperfusion. Griffiths et al²² have

identified preserved ventricular function as a significant risk factor for mortality independent of transplantation, reinforcing the need to improve our ability to identify irreversible Fontan failure in this complicated population and offer transplantation at an earlier timepoint. Pretransplantation management should focus on optimizing nutritional and functional status. We have a low threshold for admitting patients with a failing Fontan (especially those with PLE) for therapy including diuretics, inotropes, and therapeutic paracentesis. Low-dose inotropes may be helpful, even among patients with only mild ventricular dysfunction but with failing Fontan circulation.

Study Limitations

Although this is the largest single-institution series to date, the small sample size remains a significant limitation in any analysis of transplantation for the failing Fontan circulation because it limits the ability to perform multivariate analysis. Even with univariate analysis, to have a 90% chance of detecting a twofold increase in mortality from 15% to 30%, a sample of 162 patients would have been required. However, patients with failing Fontan circulation (especially when they undergo transplantation in adulthood), might not be accurately captured in any existing database, leaving small single-institution studies such as ours the only method for examining the outcomes in these patients. In addition, to maximize the number of patients we examined, it was necessary to include a long period in the analysis, and peritransplant management has changed significantly from 1984 to 2007 (as evidenced by the reduced mortality rates after the more recent transplants).

CONCLUSIONS

Despite these limitations, these data support several conclusions. First, early mortality after transplantation for the failing Fontan circulation is greater than among patients with CHD and 2 functional ventricles. The improving results during the past 2 decades reinforce the need to refer these patients to centers with experience in transplantation involving complex congenital disease; however, the perioperative mortality remains high and consideration of the use of alternate listing strategies for these patients might enable maximization of the limited supply of donor allografts. Second, the results in the most recent decade have improved, and we could not identify any patients with failed Fontan circulation not amenable to transplantation in the current era. Third, the indicators of clinical status at transplantation, including renal failure, rather than the specific diagnosis or indication for transplantation, were the strongest predictors of poor survival. Finally, perhaps the most important lesson is that early referral for transplantation—before the development of nutritional debilitation, cachexia, and even subtle end-organ injury—is crucial to optimizing

post-transplant outcomes among patients with a failing Fontan.

References

- Fontan F, Kirklin JW, Fernandez G, Costa F, Naftel DC, Tritto F, et al. Outcome after a "perfect" Fontan operation. *Circulation*. 1990;81:1520-36.
- Hosein RB, Clarke AJ, McGuirk SP, Griselli M, Stumper O, De Giovanni JV, et al. Factors influencing early and late outcome following the Fontan procedure in the current era: the "two commandments"? *Eur J Cardiothorac Surg*. 2007;31:344-53.
- Marcelletti CF, Hanley FL, Mavroudis C, McElhinney DB, Abella RF, Marianeschi SM, et al. Revision of previous Fontan connections to total extracardiac cavopulmonary anastomosis: a multicenter experience. *J Thorac Cardiovasc Surg*. 2000;119:340-6.
- Mavroudis C, Backer CL, Deal BJ, Johnsrude C, Strasburger J. Total cavopulmonary conversion and maze procedure for patients with failure of the Fontan operation. *J Thorac Cardiovasc Surg*. 2001;122:863-71.
- Lower RR, Shumway NE. Studies on orthotopic homotransplantation of the canine heart. *Surg Forum*. 1960;11:18-9.
- Davies RR, Russo MJ, Sorabella RA, Gelijns AC, Moskowitz AJ, Naka Y, et al. Cardiac transplant anastomosis and the need for permanent pacemaker implantation: an analysis of the United Network for Organ Sharing database. *J Heart Lung Transpl*. 2008;27:S136.
- Sievers HH, Weyand M, Kraatz EG, Bernhard A. An alternative technique for orthotopic cardiac transplantation, with preservation of the normal anatomy of the right atrium. *Thorac Cardiovasc Surg*. 1991;39:70-2.
- Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M, PLE Study Group. Protein-losing enteropathy after the Fontan operation: an international multicenter study. *J Thorac Cardiovasc Surg*. 1998;115:1063-73.
- Weipert J, Noebauer C, Schreiber C, Kostolny M, Zrenner B, Wacker A, et al. Occurrence and management of atrial arrhythmia after long-term Fontan circulation. *J Thorac Cardiovasc Surg*. 2004;127:457-64.
- Rychik J. Protein-losing enteropathy after Fontan operation. *Congenital Heart Dis*. 2007;2:288-300.
- Bernstein D, Naftel D, Chin C, Addonizio LJ, Gamberg P, Blume ED, et al. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. *Circulation*. 2006;114:273-80.
- Jayakumar KA, Addonizio LJ, Kichuk-Chrisant MR, Galantowicz ME, Lamour JM, Quaegebeur JM, et al. Cardiac transplantation after the Fontan or Glenn procedure. *J Am Coll Cardiol*. 2004;44:2065-72.
- Michielon G, Parisi F, Squitieri C, Carotti A, Gagliardi G, Pasquini L, et al. Orthotopic heart transplantation for congenital heart disease: an alternative for high-risk Fontan candidates? *Circulation*. 2003;108(Suppl 1):II140-9.
- Gamba A, Merlo M, Fiocchi R, Terzi A, Mammana C, Sebastiani R, et al. Heart transplantation in patients with previous Fontan operations. *J Thorac Cardiovasc Surg*. 2004;127:555-62.
- Warnes CA, Liberthson R, Danielson GK, Dore A, Harris L, Hoffman JIE, et al. Task force 1: the changing profile of congenital heart disease in adult life. *J Am Coll Cardiol*. 2001;37:1170-5.
- Chen JM, Davies RR, Mital SR, Mercado ML, Addonizio LJ, Pinney SP, et al. Trends and outcomes in transplantation for complex congenital heart disease: 1984 to 2004. *Ann Thorac Surg*. 2004;78:1352-61.
- Kanter KR, Mahle WT, Vincent RN, Berg AM, Kogon BE, Kirshbom PM. Heart transplantation in children with a Fontan procedure. *Ann Thorac Surg*. 2011;91:823-30.
- Hsu DT, Quaegebeur JM, Ing FF, Selber EJ, Lamour JM, Gersony WM. Outcome after the single-stage, nonfenestrated Fontan procedure. *Circulation*. 1997;96:II-335-40.
- Stamm C, Friehs I, Mayer JE, Zurakowski D, Triedman JK, Moran AM, et al. Long-term results of the lateral tunnel Fontan operation. *J Thorac Cardiovasc Surg*. 2001;121:28-41.
- Ghanayem NS, Berger S, Tweddell JS. Medical management of the failing Fontan. *Pediatr Cardiol*. 2007;28:465-71.
- Davies RR, Russo MJ, Mital S, Martens TM, Sorabella RS, Hong KN, et al. Predicting survival among high-risk pediatric cardiac transplant recipients: an analysis of the United Network for Organ Sharing database. *J Thorac Cardiovasc Surg*. 2008;135:147-55. 155.e1-2.
- Griffiths ER, Kaza AK, Wyler von Ballmoos MC, Loyola H, Valente AM, Blume ED, et al. Evaluating failing Fontans for heart transplantation: predictors of death. *Ann Thorac Surg*. 2009;88:558-64.

TABLE E1. Operative details for patients undergoing transplantation for failed Fontan (n = 43)

Pt. no.	CPB time	TCA time	Ischemic time	Anastomosis	Complex reconstruction
39	134	0	109	Biatrial	None
49	249	0	228	Biatrial	Donor PA used to reconstruct recipient pulmonary artery bifurcation
53	289	0	253	Biatrial	Donor PA used to reconstruct recipient pulmonary artery bifurcation
69	377	0	397	Biatrial	10-mm Dacron graft used to replace R PA
73	286	54	281	Biatrial	Donor PA used to reconstruct recipient pulmonary artery bifurcation Donor SVC used to reconstruct recipient SVC
81	147	0	152	Biatrial	Donor PA used to reconstruct recipient pulmonary artery bifurcation
82	183	0	192	Biatrial	Pericardial patch to reconstruct R PA
83	311	1	339	Biatrial	None
787	420	0	360	Bicaval	12-mm PTFE graft used to replace R PA
790	426	61	327	Bicaval	12-mm PTFE used to replace R and L PAs
87	247	65	193	Bicaval	Donor PA used to reconstruct recipient pulmonary artery bifurcation
791	369	0	172	Biatrial	Interatrial baffle to direct L SVC and L IVC to R side (situs inversus)
91	292	48	331	Biatrial	Donor PA used to reconstruct recipient pulmonary artery bifurcation Recipient coronary sinus L in situ to drain L SVC
98	253	0	270	Biatrial	Donor PA used to reconstruct recipient pulmonary artery bifurcation
99	309	0	151	Bicaval	Autologous pericardium to reconstruct R PA
379	487	50	292	Bicaval	12-mm PTFE used to replace R and L PAs
794	274	80	220	Biatrial	None
105	240	0	220	Biatrial	Donor PA used to reconstruct recipient R PA
113	188	0	239	Bicaval	Patch used to reconstruct R PA
115	205	0	190	Bicaval	None
145	330	0	343	Bicaval	Donor PA used to reconstruct recipient pulmonary artery bifurcation
155	318	0	443	Biatrial	Donor PA used to reconstruct recipient pulmonary artery bifurcation
801		0		Bicaval	Donor PA used to reconstruct recipient pulmonary artery bifurcation Bovine pericardial baffle used to connect L and R SVCs
171	243	0	330	Bicaval	Donor PA used to reconstruct recipient pulmonary artery bifurcation
198		0	202	Bicaval	Donor PA used to reconstruct recipient pulmonary artery bifurcation and R PA
203	173	0	160	Bicaval	Pulmonary homograft used to reconstruct R and L PAs
204	210	0	267	Bicaval	None
205	198	0	233	Bicaval	Donor PA used to reconstruct recipient R and L PAs
207	175	0	220	Bicaval	Transplant to single R lung, baffled PA anastomosis
234	191	18	306	Bicaval	Donor PA used to reconstruct recipient pulmonary artery bifurcation L SVC anastomosed to donor innominate vein Hemiarch replacement performed for transverse aortic arch stenosis
768	234	0		Bicaval	Donor PA used to reconstruct recipient pulmonary artery bifurcation
248	234	0	164	Bicaval	Donor PA used to replace bifurcation and R PA Donor PA used to reconstruct anterior SVC
249	351	0	285	Bicaval	Donor/recipient atrial tissue to baffle anomalous pulmonary venous return from R to L atrium Donor PA anastomosis made to previous Gore-Tex tube graft replacement of bilateral pulmonary arteries L SVC anastomosed to donor innominate vein R SVC of negligible size, oversewn
251	326	39	399	Bicaval	Site of previous Glenn shunt on R PA replaced with bovine pericardium
258	321	10	362	Bicaval	L SVC thromboembolectomy L SVC anastomosed to donor innominate vein Donor PA used to reconstruct R and L PAs Patch angioplasty of R SVC using donor aorta
261	314	0		Bicaval	Recipient R atrial tissue and donor PA used to replace pulmonary artery bifurcation
510	322	120	205	Bicaval	L SVC anastomosed to donor innominate vein Donor PA used to reconstruct pulmonary artery bifurcation

(Continued)

TABLE E1. Continued

Pt. no.	CPB time	TCA time	Ischemic time	Anastomosis	Complex reconstruction
726	244		238	Bicaval	L SVC of negligible size, oversewn Donor PA used to reconstruct R and L PAs
740	376	64	294	Bicaval	Bovine pericardial patch angioplasty of R PA Pulmonary homograft reconstruction of anterior of L and R PA
772	277	0	338	Bicaval	Unifocalization of branch pulmonary arteries Patch angioplasty of R PA using recipient atrium Donor PA used to reconstruct anterior of pulmonary artery bifurcation
757	480	54	275	Biatrial	Donor PA onlay patch angioplasty of pulmonary artery bifurcation
844	171	0	194	Bicaval	Patch angioplasty of R PA using bovine pericardium
866	176	0	133	Bicaval	Patch angioplasty of R PA using donor L atrial tissue

Pt. no., Patient number; *CPB*, cardiopulmonary bypass; *TCA*, total circulatory arrest; *PA*, pulmonary artery; *R*, right; *SVC*, superior vena cava; *PTFE*, polytetrafluoroethylene; *L*, left; *IVC*, inferior vena cava.

TABLE E2. Incidence of neurologic events for patients undergoing transplantation for failed Fontan (n = 4)

Variable	Pt. no.	Year	TCA (min)	Clinical course	Brain imaging	Clinical outcome
Stroke	82	1992	None	On ECMO before transplantation; neurologic status not clear immediately before transplantation; re-explored for bleeding; died POD 1 of intractable bleeding	None	Died POD 1
	91	1994	49	POD 4 with cardiac arrest, subsequently with decreased right-sided movement	MRI, subcortical lesions c/w hypotensive episode	Mild decrease in RUE strength at discharge; alive
	99	1994	None	Extubated POD 2 but subsequent course complicated by multiorgan system failure and cardiac arrest; POD 30 with symmetric strength, but then with cardiac arrest and then bihemispheric stroke	EEG consistent with severe bihemispheric injury	Died POD 40
	113	1995	None	No intraoperative issues; multiple seizures in postoperative period	CT, bihemispheric small infarcts, L frontal, R occipital/parietal, old pontine lesions c/w watershed infarcts	Walking with assistance, speaking sentences, severe cognitive deficits; died 6 yr after transplant
	772	2006	None	Required re-exploration for bleeding on POD 1, factor 7 given, systolic blood pressure in 80s; L upper extremity weakness noted POD 1	CT, R frontal subcortical infarct, no hemorrhage	Still with decreased strength and numbness in LUE/LLE; alive
	234	2004	18	POD 16, seizures and later facial weakness, small acute bleeding site on imaging	CT/MRI, multiple regions of arterial stenoses/dilations, tight vertebral artery stenosis, impaired cerebral perfusion; likely old caudate infarct with post-transplant bleed	Facial weakness resolved before discharge; no sequelae; alive
Subdural	510	2006	120	POD 3 with right-sided weakness	CT/MRI, small subdural hematoma, no evidence of stroke	No deficits on neurologic examination at discharge; alive
Seizure	768	2004	None	Intraoperative course with severe protamine reaction; postoperative course complicated by vasodilatory shock, renal failure, pneumonia; 2 complex partial seizures treated with Keppra	CT, no infarct, hemorrhage, mass effect	No neurologic sequelae; alive

Pt. no., Patient number; TCA, total circulatory arrest; ECMO, extracorporeal membrane oxygenation; POD, postoperative day; R, right; MRI, magnetic resonance imaging; RUE, right upper extremity; EEG, electroencephalogram; CT, computed tomography; L, left; LUE, left upper extremity; LLE, left lower extremity.

TABLE E3. Clinical course of 5 patients requiring post-transplant dialysis

Pt. no.	Age (yr)	Year	Postoperative clinical course	Preoperative clinical status	Outcome
99	13	1994	CVVH $\times$ 1 d in setting of cardiopulmonary arrest and sepsis	Normal renal function	Died POD 40
82	3	1992	Immediate postoperative course required re-exploration for bleeding, profound hypotension	On ECMO with renal failure, dialysis initiated before ECMO	Died POD 1
249	13	2005	Postoperative course complicated by sepsis, including aspergillosis, CVVH initiated on day of death	Normal renal function	Died POD 60
251	20	2005	Patient received hemodialysis intraoperatively for intractable hyperkalemia; could not be resuscitated	Normal renal function	Died POD 0 in OR
261	22	2005	Complicated postoperative course with sepsis and multiorgan system failure, CVVH required intermittently until death	Normal renal function	Died POD 63

Pt. no., Patient number; *CVVH*, continuous venovenous hemofiltration; *POD*, postoperative day; *ECMO*, extracorporeal membrane oxygenation; *OR*, operating room.